FDA DMF Submission

US FDA Drug Master File (DMF) Type II Submission & Annual Update Guide

Updated: Jun 2025QTC Global Compliance TeamRegulatory reference content

Guiding manufacturers through US FDA Type II DMF drafting and eCTD electronic submission, including Annual Reports and deficiency letter response.

Key answer

A US FDA Type II DMF is a technical main document for APIs submitted to the FDA to support formulation ANDA/NDA applications. Submissions must be formatted in eCTD (electronic Common Technical Document), with a primary focus on Module 3 (Quality). Submitter pays the GDUFA fee. Annual updates must be filed on the anniversary date to keep the DMF active.

Critical Omissions in CTD Module 3 Compilation

Upon submission, the FDA frequently issues Refuse to Receive (RTF) or deficiency letters, primarily due to insufficient justification of Critical Process Parameters (CPPs) or lack of mutagenic impurity risk analyses.

  • 3.2.S.2.6 Process Development: lacking systematic studies on impurity fate and purge
  • 3.2.S.4.3 Validation: incomplete data for specificity, precision, or LOQ; missing raw chromatograms
  • 3.2.S.7 Stability: lacking 3 commercial-scale batches packaging stability data under ICH Q1A

FAQ

What is a Letter of Authorization (LOA)?+

An LOA is a letter submitted by the API supplier to the FDA, authorizing a formulation customer to reference the DMF in their ANDA/NDA filing. Before issuing an LOA, verify that the DMF is active and has passed the FDA Completeness Assessment.

Next steps

If this topic applies to your product, facility, or supply chain requirement, start by confirming the target market, customer-required standard, existing documents, audit history, and expected timeline.